ArticleBiomedicines2022

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models.

Giuseppina Barutello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.